Compare · IDXG vs SYK
IDXG vs SYK
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $129.30B, about 5858.0x IDXG ($22.1M).
- SYK has been more active in the news (10 items in the past 4 weeks vs 3 for IDXG).
- SYK has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $22.1M
- $129.30B
- 1M return
- -
- +22.08%
- 1Y return
- -
- -5.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 3
- 10
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest IDXG
- Amendment: SEC Form S-1/A filed by Interpace Biosciences, Inc.
- SEC Form FWP filed by Interpace Biosciences, Inc.
- SEC Form 8-K filed by Interpace Biosciences, Inc.
- Amendment: SEC Form S-1/A filed by Interpace Biosciences, Inc.
- SEC Form S-1 filed by Interpace Biosciences, Inc.
- SEC Form S-8 filed by Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: Interpace Biosciences, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Interpace Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO, President & Chairman Burnell Thomas W. converted options into 1,966,763 shares and covered exercise/tax liability with 581,718 shares, increasing direct ownership by 1,954% to 1,455,927 units (SEC Form 4) to cover taxes
Latest SYK
- SEC Form S-3ASR filed by Stryker Corporation
- SEC Form IRANNOTICE filed by Stryker Corporation
- SEC Form 10-Q filed by Stryker Corporation
- Stryker downgraded by Canaccord Genuity with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker reports third quarter 2026 operating results
- Stryker to participate in the 2026 Jefferies Global Healthcare Conference
- Stryker completes acquisition of ZuriMED to enhance its shoulder offering
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery